What's Happening?
Anixa Biosciences, Inc., a biotechnology company focused on cancer treatment and prevention, has reported updated positive survival observations from its ongoing Phase 1 clinical trial of liraltagene autoleucel (lira-cel), a CAR-T therapy targeting the follicle-stimulating
hormone receptor (FSHR) for recurrent ovarian cancer. The trial, presented at the International Society for Cell & Gene Therapy 2026 Annual Meeting, shows that several patients have survived significantly beyond the expected median survival. The therapy has demonstrated a favorable safety profile, with no dose-limiting toxicities or significant adverse events related to lira-cel administration.
Why It's Important?
The positive survival data from the lira-cel trial is encouraging for patients with recurrent ovarian cancer, a condition with limited treatment options. The trial's results suggest that lira-cel could offer a new therapeutic avenue for extending survival in this patient population. The absence of significant toxicities in the early-stage study supports further clinical evaluation and dose escalation. Anixa's collaboration with Moffitt Cancer Center and the use of novel CAR-T technology highlight the potential for innovative treatments in oncology, potentially improving outcomes for patients with advanced cancer.
What's Next?
Anixa plans to continue the trial with the next dose cohort, which will evaluate a higher dose and include lymphodepletion to enhance CAR-T cell expansion and activity. The company aims to further assess the therapy's safety and efficacy, with the potential for broader clinical application if successful. The ongoing trial will continue to enroll patients with recurrent ovarian cancer who have progressed after at least two prior therapies, with the goal of determining the maximum tolerated dose and preliminary clinical activity.
